Lasofoxifene Tartrate

酒石酸拉索昔芬

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameLasofoxifene Tartrate
Drug Alias Name拉索昔芬lasofoxifenolasofoxifenumlasofoxifeneOporia +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptor alpha modulatorsEstrogen receptor beta agonistsEstrogen receptors modulators
TargetsEstrogen receptorsEstrogen receptor alphaEstrogen receptor beta
Therapy Area/IndicationsMetastatic breast cancerOsteoporosisBone Diseases, Metabolic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[36] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer IncLigand Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesCatalent Greenville IncChiva Pharmaceuticals IncSermonix Pharmaceuticals Inc +[5] 
Inactive CompaniesLigand Pharmaceuticals Inc
Active IndicationsMetastatic breast cancerBreast Neoplasms
Inactive IndicationsOsteoporosisBone Diseases, Metabolic

Other Information

ATC CodeG03
Related LinksWikipediaDrugBankKEGG